[Federal Register Volume 73, Number 157 (Wednesday, August 13, 2008)]
[Notices]
[Page 47137]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E8-18705]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army


Intent To Grant an Exclusive License of a U.S. Government-Owned 
Patent

AGENCY: Department of the Army, DoD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In accordance with 35 U.S.C. 209(e) and 37 CFR 404.7(a)(I)(i), 
announcement is made of the intent to grant an exclusive, royalty-
bearing, revocable license to U.S. Patent No. 6,451,309 entitled 
``Prophylactic and Therapeutic Monoclonal Antibodies,'' issued 
September 17, 2002; and U.S. Patent No. 6,620,412 entitled, 
``Prophylactic and Therapeutic Monoclonal Antibodies,'' issued 
September 16, 2003, which is a continuation of U.S. Patent No. 
6,451,309, and foreign rights to BioFactura, Inc., with its principal 
place of business at 9700 Great Seneca Highway, Rockville, Maryland 
20850.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, 
Frederick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: For licensing issues, Dr. Paul Mele, 
Office of Research & Technology Assessment, (301) 619-6664. For patent 
issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808, both at 
telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: Anyone wishing to object to the grant of 
this license can file written objections along with supporting 
evidence, if any, 15 days from the date of this publication. Written 
objections are to be filed with the Command Judge Advocate (see 
ADDRESSES).

Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. E8-18705 Filed 8-12-08; 8:45 am]
BILLING CODE 3710-08-P